Information for donors
Your generosity will continue to be directed where it matters most: supporting patients and strengthening the safety net they rely on.
A note from Alan Klein, Chief Growth & Strategy Officer
As Chief Growth and Strategy Officer for Patient Advocate Foundation, we are thrilled that patients and their stakeholders will be able to find financial assistance and so many other resources in a single place. I want to reassure you that the core of our work remains unchanged and there will be no disruption of services for patients, including financial assistance grants. This is a tremendous opportunity to expand services, simplify access, and reach millions more people facing the growing healthcare access and affordability crisis here in the U.S.
Below, you can learn more about what our strategic merger means for donors like you, or reach out to me and my team to learn more. We thank you for your continued support as we help patients navigate, access, and afford the care they need.
Alan Klein
Chief Growth & Strategy Officer
Your impact, amplified
As always, we deeply thank you for your generosity and belief in our mission. Your support has always been about one thing: helping patients get the care they need—and that purpose remains unchanged.
The merger of Patient Advocate Foundation and the PAN Foundation allows us to build on that shared mission by reaching more people and offering more comprehensive support. By bringing together complementary programs, expertise, and infrastructure, we’re expanding our ability to respond to rising healthcare costs and growing barriers to care, without losing sight of the individuals and families at the heart of this work.
Your contributions will continue to support the same core mission you’ve invested in: helping patients afford treatment, navigate complex healthcare challenges, and overcome obstacles that stand in the way of care.
Reports and financials
Patient Advocate Foundation
PAN Foundation
Identified need funds
In addition to the over 130 funds for which we have already officially opened and provided financial assistance to patients, Patient Advocate Foundation has identified the following disease funds through an independent, rigorous research process, including through our case management data. We define our disease funds in accordance with widely recognized clinical standards, specifically using ICD-10 codes to specify the clinical scope and to supplement the definition of a widely recognized disease state. These programs are awaiting initial donations.
Patient Advocate Foundation has sole discretion in identifying new disease funds and is not influenced by, nor do we accept, recommendations from donors regarding the design of a disease fund. In addition, we will not create a new disease fund in response to a donor request.
A-C
Abetalipoproteinemia (Bassen-Kornzweig Syndrome)
Achondroplasia
Actinic Keratosis
Acute Lymphoblastic Leukemia
Addison’s Disease/Adrenal Insufficiency
Adrenoleukodystrophy
Adult Onset Still’s Disease
Adult T-Cell Leukemia/Lymphoma
Alagille Syndrome
Alcohol Use Disorder
Alopecia Areata
Alpha-1 Antitrypsin (AAT) Deficiency
Alpha-Mannosidosis
Alport Syndrome
Alzheimer’s Disease
Amyotrophic Lateral Sclerosis (ALS)
Anal Cancer
Anaphylaxis (Acute Reaction Prevention Fund)
Anaplastic Large Cell Lymphoma
Angelman Syndrome
Angioimmunoblastic T-cell Lymphoma
Angiosarcoma
Ankylosing Spondylitis
Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (AAV)
Antithrombin Deficiency
Anxiety Disorders
Aplastic Anemia
Aspergillosis Infections
Astrocytoma
Ataxia-Telangiectasia
Atrial Fibrillation and Flutter
Attention Deficit Disorder Hyperactivity (ADD/ADHD)
Atypical Teratoid/Rhabdoid Tumor (AT/RT)
Autism Spectrum Disorder
Barrett’s Esophagus
Barth Syndrome
Batten Disease
Becker Muscular Dystrophy
Behcet’s Syndrome
Benign Prostatic Hyperplasia (BPH)
Bile Acid Synthesis Disorders
Biliary Atresia
Binge Eating Disorder
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Blepharitis
Bone Metastases
Botulism
Brain Cancer
Bronchiectasis
Bronchiolitis Obliterans
Bullous Pemphigoid
Burkitt Lymphoma
Calciphylaxis
Cancers of the Renal Pelvis and Ureter
Carcinoid Syndrome
Carcinoid Tumors
Cardiac Arrhythmias
Cardiomyopathy
CDKL5 Disorder
Celiac Disease
Cerebrotendinous Xanthomatosis (CTX)
Cervical Dystonia (Spasmodic Torticollis)
Charcot-Marie-Tooth Disease
Chemotherapy Induced Anemia
Chordoma
Chronic Bronchitis
Chronic Granulomatous Disease
Chronic Iron or Lead Overload
Chronic Myeloid or Myelogenous Leukemia
Chronic Myelomonocytic Leukemia (CMML)
CIAS1 Associated Periodic Syndromes (CAPS)
Cirrhosis
Classical Hodgkin Lymphoma
Clostridium Difficile-Associated Diarrhea (CDAD)
CLOVES Syndrome
Cluster Headaches
Complex Regional Pain Syndrome
Congenital Adrenal Hyperplasia
Congenital Fibrinogen Deficiency
Congenital Hyperinsulinism
Congenital Plasminogen Deficiency
Congenital Sucrase-isomaltase Deficiency
Congenital Varicella Syndrome
Coronary Artery Disease (CAD)
Cutaneous Squamous Cell Carcinoma
Cutaneous T-Cell Lymphoma
Cystinosis
Cystinuria
Cytomegaloviral Infection Treatment and Prevention
D-K
Deep Venous Thrombosis
Deficiency of IL-1 Receptor Antagonist (DIRA)
Depression/Major Depressive Disorder
Dermatitis Herpetiformis
Dermatofibrosarcoma Protuberans (DFSP)
Dermatomyositis
DiGeorge Syndrome
Doose Syndrome
Dravet Syndrome
Dry Eye Syndrome
Dupuytren’s Disease
Endometriosis
Enteropathy-Associated Intestinal T-cell Lymphoma (EATL)
Eosinophilic Gastroenteritis
Eosinophilic Granulomatosis with Polyangiitis
Ependymoma
Epidermolysis Bullosa
Epilepsy
Epithelioid Sarcoma
Erdheim-Chester Disease
Erythrodermic Psoriasis
Esophageal Cancer
Essential Tremor
Ewing’s Sarcoma
Exocrine Pancreatic Insufficiency
Extranodal Natural Killer/T-cell Lymphoma, Nasal Type
Factor X Deficiency
Fallopian Tube Cancer
Familial Chylomicronemia Syndrome
Familial Cold Autoinflammatory Syndrome (FCAS)
Familial Mediterranean Fever
Fibrodysplasia Ossificans Progressiva
Focal Segmental Glomerulosclerosis
Fragile X Syndrome
Friedreich’s Ataxia
Galactosemia
Gastric (Stomach) Cancer
Gastroesophageal Junction Adenocarcinoma
Gastroparesis
Generalized Anxiety
Geographic Atrophy
Giant Cell Arteritis
Glaucoma
Glomerulonephritis
Gout
Granulomatosis with Polyangiitis (GPA)/Wegener’s Granulomatosis
Graves’ Disease
Growth Hormone Deficiency
Guillain-Barre Syndrome
Hairy Cell Leukemia
Hashimoto’s Disease
Head & Neck Cancer
Hearing Loss
Hemophagocytic Lymphohistiocytosis (HLH)
Hereditary Angioedema
Hereditary Xerocytosis
Hidradenitis Suppurativa
Hodgkin Lymphoma
Homocystinuria
Human Papillomavirus Infection
Huntington’s Disease
Hypercalcemia
Hypereosinophilic Syndrome (HES)
Hyperhidrosis
Hyperlipidemia
Hyperparathyroidism
Hyperphosphatemia
Hypertension
Hypertriglyceridemia
Hypertrophic Cardiomyopathy
Hypogonadism
Hypoparathyroidism
Hypophosphatemia
Idiopathic Hypersomnia
Idiopathic Intracranial Hypertension
Idiopathic Thrombocytopenic Purpura
IgA Nephropathy
Immunoglobulin G4-related Disease
Inclusion Body Myositis
Infantile Neuroaxonal Dystrophy (INAD)
Inflammatory Myofibroblastic Tumor (IMT)
Inherited Icthyoses
Interstitial Cystitis
Interstitial Lung Disease
Interstitial Lung Disease associated with Systemic Sclerosis or Scleroderma
Iron Deficiency Anemia
Irritable Bowel Syndrome
Juvenile Idiopathic Arthritis
Kaposi’s Sarcoma
Krabbe Disease
L-P
Lambert-Eaton Myasthenic Syndrome
Leber’s Hereditary Optic Neuropathy
Legionnaires’ Disease
Leiomyosarcoma
Lennox-Gastaut Syndrome
Leprosy
Lewy Body Dementia
Lichen Planus
Limb-Girdle Muscular Dystrophy
Lipedema
Liposarcoma
Long QT Syndrome
Lyme Disease
Lymphangioleiomyomatosis (LAM)
Mannose Phosphate Isomerase Deficiency
Marginal Zone Lymphomas
Mast Cell Activation Disorders
Mastocytosis
Menkes Disease
Merkel Cell Carcinoma
Mesothelioma
Methylmalonic Acidemia
Microscopic Polyangiitis (MPA)
Migraine
Minimal Change Disease (MCD)
Molybdenum Cofactor Deficiency
Muckle-Wells Syndrome (MWS)
Mucopolysaccharidosis Type I (Hurler, Hurler-Scheie and Scheie Syndrome)
Mucopolysaccharidosis Type II (Hunter Syndrome)
Mucopolysaccharidosis Type IV (Morquio Syndrome)
Mucopolysaccharidosis Type VI (Maroteaux-Lamy Syndrome)
Multifocal Motor Neuropathy
Multiple System Atrophy (MSA)
Muscular Dystrophy
Myeloproliferative Disorders
Neonatal Onset Multisystem Inflammatory Disease (NOMID)
Netherton Syndrome
Neuroblastoma
Neurocognitive Disease with Psychosis
Neuroendocrine Tumors
Neuroendocrine Tumors of GI Tract
Neuroendocrine Tumors of Lungs
Neuroendocrine Tumors of Pancreatic Origin
Neuronal Ceroid Lipofuscinoses
Nicotine Addiction
Niemann-Pick Disease
Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)
Non-Arteric Ischemic Anterior Optic Neuropathy
Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
Nontuberculous Mycobacterial Infections
Obsessive Compulsive Disorders
Obstructive Sleep Apnea (OSA)
Ohtahara Syndrome
Oligodendroglioma
Open Angle Glaucoma
Opioid Use Disorder
Osteoarthritis
Osteosarcoma
Overactive Bladder
Pachyonychia Congenita
Paget’s Disease
Panayiotopoulos Syndrome (Childhood Autonomic Epilepsy)
Pantothenate Kinase-Associated Neurodegeneration
Paraganglioma & Pheochromocytoma
Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS)
Pediatric Glioma
Periodontitis
Pernicious Anemia
Peyronie’s Disease
Phenylketonuria (PKU)
Pheochromocytoma and Paraganglioma
Polycystic Kidney Disease (PKD)
Polycystic Ovary Syndrome (PCOS)
Polymyalgia Rheumatica
Polymyositis & Dermatomyositis
Porphyria
Post-Partum  depression
Post-Transplant Lymphoproliferative Disorders
Post-Traumatic Stress Disorder
Pouchitis
Prader-Willi Syndrome
Premenstrual Dysphoric Disorder (PMDD)
Primary Biliary Cholangitis
Primary Hyperoxaluria
Primary Immunodeficiency Diseases (PIDD)
Primary Mitochondrial Myopathy
Progeria
Progressive Familial Intrahepatic Cholestasis (PFIC)
Propionic Acidemia
Protein C Deficiency
Prurigo Nodularis
Pulmonary Alveolar Proteinosis
Pulmonary Embolism
Pustular Psoriasis
Pyruvate Dehydrogenase Complex Deficiency
Pyruvate Kinase Deficiency
R-Z
Retinopathy of Prematurity
Rhabdomyosarcoma
Rosacea
Sarcoidosis
Sarcoma of the Bone
Seasonal Affective Disorder
Secondary Hyperoxaluria
Severe Combined Immunodeficiency Disease (SCID)
Shingles Treatment and Prevention
Sjögren’s Syndrome
Smith-Magenis Syndrome
Social Anxiety Disorder
Soft Tissue Sarcoma
Solid Organ Transplant Preservation and Rejection Prevention
Spinocerebellar Ataxia
Stargardt Disease
Synovial Sarcoma
Syphilis
Systemic Mastocytosis
Systemic Sclerosis (Scleroderma)
Tardive Dyskinesia
Tay-Sachs Disease
Tenosynovial Giant Cell Tumor (TGCT)
Testicular Cancer
Thalassemia
Thrombocytopenia
Thyroid Cancer
Tourette’s Syndrome
Trigeminal Neuralgia
Tuberculosis
Tuberous Sclerosis Complex
Turner’s Syndrome
Type 1 Diabetes
Urea Cycle Disorders
Urticaria
Uterine Fibroids
Vaginal Atrophy
Vascular Ehlers-Danlos Syndrome (vEDS)
Veno-Occlusive Disease (VOD)
Ventricular Fibrillation and Flutter
Virology Testing Fund
Von Hippel-Lindau (VHL) Disease
Vulvar Cancer
West Syndrome
WHIM Syndrome
Wilms Tumor
Wilson Disease
Xeroderma Pigmentosum
X-Linked Agammaglobulinemia (XLA)
X-Linked Hypophosphatemia
Zellweger Spectrum Disorders
Zollinger-Ellison Syndrome
Contact us
Alan Klein, Chief Growth & Strategy Officer, will serve as the primary donor contact to ensure meaningful and transparent donor engagement.
Alan is an accomplished business development officer and patient advocate with a track record of expertise in access-to-care initiatives and successfully expanding mission impact for nonprofit organizations. As Chief Growth and Strategy Officer at Patient Advocate Foundation, he develops and scales support for education, advocacy, case management, and financial assistance programs and initiatives that accelerate access to affordable, equitable healthcare and improve health outcomes.
With more than 30 years leading business development and management strategies in the healthcare nonprofit and pharmaceutical sectors, Alan brings a deep commitment to advancing healthcare equity.
Previously, Alan served as Chief Development Officer at HealthWell Foundation. His career also includes leadership roles in the pharmaceutical sector managing large-scale transactions, revenue growth, and strategic product development. Throughout his career, Alan has spent more than 30 years in senior-level business development and management positions at pre-revenue, small, and large organizations within the pharmaceutical and biotechnology industries. In addition, he has been responsible for the management of revenue growth and portfolio investments, profit management, and supervision of strategic product development programs in these prior roles.
Alan received his MBA from Johns Hopkins University and a BA from the University of Maryland.
"*" indicates required fields
Help center
Use our help center to find answers to questions that impact you, so you can make the most informed decisions.
News
Read the latest news about our merger and programs, access our media kit, and sign up for updates.
Contact us
Reach out with any questions or concerns. We will get in touch with you as quickly as possible.